

## WEST Search History





DATE: Monday, May 28, 2007

Hide?	Set Name	Query	Hit Count
<i>DB=USPT; PLUR=YES; OP=OR</i>			
<input type="checkbox"/>	L12	5264557.pn.	1
<input type="checkbox"/>	L11	6270777.pn.	1
<input type="checkbox"/>	L10	6544518 .pn.	1
<input type="checkbox"/>	L9	cripto.clm.	11
<input type="checkbox"/>	L8	5650285.pn.	1
<i>DB=EPAB,DWPI; PLUR=YES; OP=OR</i>			
<input type="checkbox"/>	L7	5650285.pn.	1
<input type="checkbox"/>	L6	"Sanicola-Nadel"	27
<input type="checkbox"/>	L5	wo000222808\$	0
<i>DB=EPAB; PLUR=YES; OP=OR</i>			
<input type="checkbox"/>	L4	wo000222808\$	0
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR</i>			
<input type="checkbox"/>	L3	5620866.pn.	2
<input type="checkbox"/>	L2	5264557.pn.	2
<input type="checkbox"/>	L1	6812339.pn.	2

END OF SEARCH HISTORY

RESULT 1

US-10-390-566-2

; Sequence 2, Application US/10390566

; Publication No. US20030232755A1

; GENERAL INFORMATION:

; APPLICANT: Williams, Kevin P.

; APPLICANT: Foley, Susan

; APPLICANT: Schiffer, Susan

; APPLICANT: Domon, Bruno

; APPLICANT: Sanicola-Nadel, Michele

; TITLE OF INVENTION: Cripto Mutant and Uses Thereof

; FILE REFERENCE: BGN-A104

; CURRENT APPLICATION NUMBER: US/10/390,566

; CURRENT FILING DATE: 2003-03-17

; PRIOR APPLICATION NUMBER: 60/233,148

; PRIOR FILING DATE: 2000-09-18

; PRIOR APPLICATION NUMBER: PCT/US01/29066

; PRIOR FILING DATE: 2001-09-18

; NUMBER OF SEQ ID NOS: 37

; SOFTWARE: FastSEQ for Windows Version 4.0

; SEQ ID NO 2

; LENGTH: 188

; TYPE: PRT

; ORGANISM: Homo Sapien

US-10-390-566-2

Query Match 100.0%; Score 188; DB 4; Length 188;

Best Local Similarity 100.0%; Pred. No. 3.8e-179;

Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Query Match 100.0%; Score 188; DB 4; Length 188;

Best Local Similarity 100.0%; Pred. No. 3.8e-179;

Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

Qy      1 MDCRKMVRFSSYVWIMAIKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAAIR 60
          |||
Db      1 MDCRKMVRFSSYVWIMAIKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAAIR 60

Qy     61 PRSSQRLVPMGIQHSKELNRTCCLNNGGTCMLESFCACPPSFYGRNCEHDVRKENCOSVPH 120
          |||
Db     61 PRSSQRLVPMGIQHSKELNRTCCLNNGGTCMLESFCACPPSFYGRNCEHDVRKENCOSVPH 120

Qy    121 DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDHLVASRTPELPPSARTTTTFLAGI 180
          |||
Db    121 DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDHLVASRTPELPPSARTTTTFLAGI 180

Qy    181 CLSIQSY 188
          |||
Db    181 CLSIQSY 188

```

RESULT 1

US-09-949-016-7062

; Sequence 7062, Application US/09949016

; Patent No. 6812339

; GENERAL INFORMATION:

; APPLICANT: VENTER, J. Craig et al.

; TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED  
 ; TITLE OF INVENTION: WITH HUMAN DISEASE, METHODS OF DETECTION AND USES THEREOF  
 ; FILE REFERENCE: CL001307  
 ; CURRENT APPLICATION NUMBER: US/09/949,016  
 ; CURRENT FILING DATE: 2000-04-14  
 ; PRIOR APPLICATION NUMBER: 60/241,755  
 ; PRIOR FILING DATE: 2000-10-20  
 ; PRIOR APPLICATION NUMBER: 60/237,768  
 ; PRIOR FILING DATE: 2000-10-03  
 ; PRIOR APPLICATION NUMBER: 60/231,498  
 ; PRIOR FILING DATE: 2000-09-08  
 ; NUMBER OF SEQ ID NOS: 207012  
 ; SOFTWARE: FastSEQ for Windows Version 4.0  
 ; SEQ ID NO 7062  
 ; LENGTH: 192  
 ; TYPE: PRT  
 ; ORGANISM: Human  
 US-09-949-016-7062

```

Query Match          100.0%;  Score 1048;  DB 2;  Length 192;
Best Local Similarity 100.0%;  Pred. No. 4.7e-100;
Matches 188;  Conservative 0;  Mismatches 0;  Indels 0;  Gaps 0;

Qy      1  MDCRKMVRFSYSVIWIMAISKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAIR 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      5  MDCRKMVRFSYSVIWIMAISKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAIR 64

Qy     61  PRSSQRVLPMDGIQHSKELNRTCCLNGGTCMLESFCACPPSFYGRNCEHDVRKENCGSVPH 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     65  PRSSQRVLPMDGIQHSKELNRTCCLNGGTCMLESFCACPPSFYGRNCEHDVRKENCGSVPH 124

Qy    121  DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDHLVASRTPELPPSARTTTFMLAGI 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    125  DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDHLVASRTPELPPSARTTTFMLAGI 184

Qy    181  CLSIQSY 188
          |||||||
Db    185  CLSIQSY 192
  
```

RESULT 2  
 US-07-749-001-5  
 ; Sequence 5, Application US/07749001  
 ; Patent No. 5264557  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Salomon, David S.  
 ; APPLICANT: Persico, Maria G.  
 ; TITLE OF INVENTION: A HUMAN CRIPTO-RELATED GENE  
 ; NUMBER OF SEQUENCES: 4  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: CUSHMAN, DARBY & CUSHMAN  
 ; STREET: 1615 L Street, N.W.  
 ; CITY: Washington  
 ; STATE: D.C.  
 ; COUNTRY: USA  
 ; ZIP: 20036  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/07/749,001  
 ; FILING DATE: 19910823  
 ; CLASSIFICATION: 435

; ATTORNEY/AGENT INFORMATION:  
; NAME: Scott, Watson T.  
; REGISTRATION NUMBER: 26,581  
; REFERENCE/DOCKET NUMBER: WTS/5683/91630/SRL  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 861-3000  
; TELEFAX: (202)822-0944  
; TELEX: 248453 CUSH  
; INFORMATION FOR SEQ ID NO: 5:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 188 amino acids  
; TYPE: AMINO ACID  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-07-749-001-5

Query Match 98.6%; Score 1033; DB 1; Length 188;  
Best Local Similarity 98.9%; Pred. No. 1.6e-98;  
Matches 186; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy	1	MDCRKMVRFSSYVIWIMAISKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAIR	60
Db	1	MDCRKMVRFSSYVIWIMAISKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAIR	60
Qy	61	PRSSQRVLPMDGIQHSKELNRTCCLMGGTCMLESFCACPPSFYGRNCEHDVRKENC GSVPH	120
Db	61	PRSSQRVLPMDGIQHSKELNRTCCLMGGTCMLESFCACPPSFYGRNCEHDVRKENC GSVPH	120
Qy	121	DTWLPPKCSLCKCWHGQLRCFPQAFLPGCDGLVMDHLVASRTPELPPSARTTTTFMLAGI	180
Db	121	DTWLPPKCSLCKCWHGQLRCFPQAFLPGCDGLVMDHLVASRTPELPPSARTTTTFMLAGI	180
Qy	181	CLSIQSY	188
Db	181	CLSIQSY	188

# RESULT 3

US-08-154-198-5

; Sequence 5, Application US/08154198  
; Patent No. 5620866  
; GENERAL INFORMATION:  
; APPLICANT: SALOMON, David S.  
; APPLICANT: PERSICO, Maria G.  
; TITLE OF INVENTION: A HUMAN CRIPTO-RELATED GENE  
; NUMBER OF SEQUENCES: 5  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Townsend and Townsend Kourie and Crew  
; STREET: Steuart Street Tower, One Market Plaza  
; CITY: San Francisco  
; STATE: California  
; COUNTRY: US  
; ZIP: 94105-1493  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/154,198  
; FILING DATE: 17-NOV-1993  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/749,001  
; FILING DATE: 23-AUG-1991  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Bastian, Kevin L.  
; REGISTRATION NUMBER: 34,774

; REFERENCE/DOCKET NUMBER: 15280-63-1  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: (415) 543-9600  
 ; TELEFAX: (415) 543-5043  
 ; INFORMATION FOR SEQ ID NO: 5:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 188 amino acids  
 ; TYPE: amino acid  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: protein  
 US-08-154-198-5

```

Query Match          98.6%; Score 1033; DB 1; Length 188;
Best Local Similarity 98.9%; Pred. No. 1.6e-98;
Matches 186; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1 MDCRKMVRFSYSVIWIMAIKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAIR 60
      |||
Db      1 MDCRKMVRFSYSVIWIMAIKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAIR 60

Qy      61 PRSSQVRVLPNGIQHSKELNRTCCLNGGTCMLSEFCACPPSFYGRNCEHDVRKENC GSVPH 120
      |||
Db      61 PRSSQVRVLPNGIQHSKELNRTCCLNEGTCMLGSFCACPPSFYGRNCEHDVRKENC GSVPH 120

Qy      121 DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTTFMLAGI 180
      |||
Db      121 DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTTFMLAGI 180

Qy      181 CLSIQSY 188
      |||
Db      181 CLSIQSY 188
  
```

## RESULT 2

A30362  
 teratocarcinoma-derived growth factor 1 - human  
 N;Alternate names: CRIPTO protein  
 C;Species: Homo sapiens (man)  
 C;Date: 18-Oct-1989 #sequence\_revision 18-Oct-1989 #text\_change 09-Jul-2004  
 C;Accession: B39787; A30362  
 R;Dono, R.; Montuori, N.; Rocchi, M.; De Ponti-Zilli, L.; Ciccodicola, A.; Persico, M.G.  
 Am. J. Hum. Genet. 49, 555-565, 1991  
 A;Title: Isolation and characterization of the CRIPTO autosomal gene and its X-linked related sequence.  
 A;Reference number: A39787; MUID:91353571; PMID:1882841  
 A;Accession: B39787  
 A;Status: preliminary  
 A;Molecule type: DNA  
 A;Residues: 1-188 <DON>  
 A;Cross-references: UNIPROT:P13385; UNIPARC:UPI000004966D; GB:M96955; GB:M37099; NID:g339430; PID:g339431  
 R;Ciccodicola, A.; Dono, R.; Obici, S.; Simeone, A.; Zollo, M.; Persico, M.G.  
 EMBO J. 8, 1987-1991, 1989  
 A;Title: Molecular characterization of a gene of the 'EGF family' expressed in undifferentiated human NTERA2 teratocarcinoma cells.  
 A;Reference number: A30362; MUID:90005403; PMID:2792079  
 A;Accession: A30362  
 A;Molecule type: mRNA  
 A;Residues: 1-188 <CIC>  
 A;Cross-references: UNIPARC:UPI000004966D; GB:X14253; NID:g30220; PIDN:CAA32467.1; PID:g30221  
 C;Superfamily: teratocarcinoma-derived growth factor 1; EGF homology  
 C;Keywords: growth factor  
 F;78-106/Domain: EGF homology <EGF>

Query Match 96.7%; Score 1013; DB 2; Length 188;  
 Best Local Similarity 96.8%; Pred. No. 2e-86;  
 Matches 182; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

```

Qy      1 MDCRKMVRFSYSVIWIMAIKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEPAIR 60
        ||||| ||||||||||||| ||||||||||||||||| |||||||||||||||||
Db      1 MDCRKMARFSYSVIWIMAIKVFELGLVAGLGHQEFARPSRGYLAFRDDSIWPQEPAIR 60

Qy     61 PRSSQRVLPMMGIQHSKELNRTCCLNNGGTCMLSEFCACPPSFYGRNCEHDVRKENCGSVPH 120
        ||||| ||||||||||||| ||||||||||||||||| |||||||||||||||||
Db     61 PRSSQRVPPMMGIQHSKELNRTCCLNNGGTCMLGSEFCACPPSFYGRNCEHDVRKENCGSVPH 120

Qy    121 DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTTFMLAGI 180
        ||||| ||||||||||||| ||||||||||||||||| |||||||||||||||||
Db    121 DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTTFMLVGI 180

Qy    181 CLSIQSY 188
        |||||
Db    181 CLSIQSY 188
  
```

# ESULT 1

ABB77102

ID ABB77102 standard; protein; 188 AA.

XX

AC ABB77102;

XX

DT 08-OCT-2002 (first entry)

XX

DE Human Cripto-3 full length protein.

XX

KW Human; Cripto-1; CR-1; mutant; tumour; Cripto-3; CR-3;

KW cell proliferation.

XX

OS Homo sapiens.

XX

PN WO200222808-A2.

XX

PD 21-MAR-2002.

XX

PF 18-SEP-2001; 2001WO-US029066.

XX

PR 18-SEP-2000; 2000US-0233148P.

XX

PA (BIOJ ) BIOGEN INC.

XX

PI Williams KP, Foley S, Schiffer S, Domon B, Sanicola-Nadel M;

XX

DR WPI; 2002-339868/37.

DR N-PSDB; ABB55853.

XX

PT New mutant form of CRIPTO (teratocarcinoma-derived growth factor), useful

PT for treating cell proliferation, especially cancer, comprises amino acid

PT change that prevents fucosylation at Thr88.

XX

PS Claim 2; Fig 1; 41pp; English.

XX

CC The sequence represents the full length human Cripto-3 protein. The  
 CC invention relates to a novel mutant CRIPTO polypeptide, or its functional  
 CC fragment, having at least one amino acid alteration at positions 86, 87  
 CC or 88. The mutant polypeptide, or its chimera, is used to inhibit growth  
 CC of tumour cells, in vivo or in vitro, particularly for treating breast,  
 CC ovarian, renal, colorectal, uterine, prostatic, lung, bladder or central  
 CC nervous system cancers, melanoma and leukaemia, also generally for  
 CC treating undesired cell proliferation

XX

SQ Sequence 188 AA;

Query Match 100.0%; Score 1048; DB 5; Length 188;  
Best Local Similarity 100.0%; Pred. No. 4.7e-85;  
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 1 MDCRKMRFSYSVIWIMAIKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAIR 60
   ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MDCRKMRFSYSVIWIMAIKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAIR 60

QY 61 PRSSQRVLPNGIQHSKELNRTCCLNGGTCMLSEFCACPPSFYGRNCEHDVRKENC GSVPH 120
   ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 PRSSQRVLPNGIQHSKELNRTCCLNGGTCMLSEFCACPPSFYGRNCEHDVRKENC GSVPH 120

QY 121 DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTTFMLAGI 180
   ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTTFMLAGI 180

QY 181 CLSIQSY 188
   |||||||
Db 181 CLSIQSY 188
```

RESULT 11

AAW25667

ID AAW25667 standard; protein; 188 AA.

XX

AC AAW25667;

XX

DT 25-MAR-2003 (revised)

DT 04-NOV-1997 (first entry)

XX

DE Protein encoded by CRIPTO-related gene, CR-3.

XX

KW CRIPTO-related gene; CR-3; epidermal growth factor; EGF; TGF-alpha;

KW amphiregulin; tumour specific marker; colon cancer cell line;

KW colorectal tumour; mesenchyme; epithelial cell.

XX

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT Misc-difference 7

FT /note= "Ala>Val mutation"

FT Misc-difference 22

FT /note= "Val>Ala mutation"

FT Misc-difference 43

FT /note= "Tyr>Asp mutation"

FT Misc-difference 68

FT /note= "Pro>Leu mutation"

FT Misc-difference 86

FT /note= "Gly>Glu mutation"

FT Misc-difference 178

FT /note= "Val>Ala mutation"

XX

PN US5650285-A.

XX

PD 22-JUL-1997.

XX

PF 05-JUN-1995; 95US-00463335.

XX

PR 23-AUG-1991; 91US-00749001.

PR 17-NOV-1993; 93US-00154198.

XX

PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.

XX

PI Persica MG, Salomon DS;

XX  
 DR WPI; 1997-384668/35.  
 DR N-PSDB; AAT80987.  
 XX  
 PT Assays for CRIPTO-related gene product CR-3 - used in studies on the  
 PT regulation of the proliferation, differentiation and transformation of  
 PT cells.  
 XX  
 PS Claim 2; Fig 2; 25pp; English.  
 XX  
 CC This sequence is encoded by the CRIPTO-related gene, CR-3. The CR-3 gene  
 CC sequence is identical to the human CRIPTO gene with the exception of  
 CC eight base pair substitutions that give rise to six amino acid changes.  
 CC CR-3 exhibits partial amino acid sequence homology and a tertiary  
 CC structure within a 38 amino acid region similar to the epidermal growth  
 CC factor (EGF) supergens family that includes EGF, TGF-alpha and  
 CC amphiregulin. Expression of CR-3 may serve as a tumour specific marker as  
 CC it is expressed in several human colon cancer cell lines and possibly in  
 CC human colorectal tumours. The assay of the amount of CR-3 in a sample can  
 CC be used in studies on the regulation of the proliferation,  
 CC differentiation, and transformation of various mesenchymal and epithelial  
 CC cells. Study of the expression of CR-3 may also be used in the diagnosis,  
 CC prognosis and treatment of tumours. (Updated on 25-MAR-2003 to correct PF  
 CC field.)

```

Query Match          98.6%;  Score 1033;  DB 2;  Length 188;
Best Local Similarity 98.9%;  Pred. No. 1e-83;
Matches 186;  Conservative 0;  Mismatches 2;  Indels 0;  Gaps 0;

Qy      1  MDCRKMVRFSYSVIWIMAISKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAIR 60
      ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1  MDCRKMVRFSYSVIWIMAISKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAIR 60

Qy     61  PRSSQRVLPNGIQHSKELNRTCCLNGGTCMLSEFCACPPSFYGRNCEHDVRKENCGSVPH 120
      |||||||||||||||||| |||| ||||||||||||||||||||||||||
Db     61  PRSSQRVLPNGIQHSKELNRTCCLNEGTCMLGSEFCACPPSFYGRNCEHDVRKENCGSVPH 120

Qy    121  DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTFMLAGI 180
      ||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121  DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTFMLAGI 180

Qy    181  CLSIQSY 188
      |||||||
Db    181  CLSIQSY 188
  
```

RESULT 3  
 US-10-945-853-4  
 ; Sequence 4, Application US/10945853  
 ; Publication No. US20050255117A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Biogen, Inc.  
 ; APPLICANT: Sanicola-Nadel, Michele  
 ; APPLICANT: Adkins, Heather  
 ; APPLICANT: Miklasz, Steven Donald  
 ; APPLICANT: Rayhorn, Paul  
 ; APPLICANT: Schiffer, Susan Gail  
 ; APPLICANT: Williams, Kevin  
 ; TITLE OF INVENTION: Cripto-Specific Antibodies



```

; FILE REFERENCE: BGNA117CPPCCN
; CURRENT APPLICATION NUMBER: US/10/945,853
; CURRENT FILING DATE: 2004-09-20
; PRIOR APPLICATION NUMBER: PCT/US02/31462
; PRIOR FILING DATE: 2002-10-01
; PRIOR APPLICATION NUMBER: PCT/US02/11950
; PRIOR FILING DATE: 2002-04-17
; PRIOR APPLICATION NUMBER: 60/286,782
; PRIOR FILING DATE: 2001-04-26
; PRIOR APPLICATION NUMBER: 60/293,020
; PRIOR FILING DATE: 2001-05-17
; PRIOR APPLICATION NUMBER: 60/301,091
; PRIOR FILING DATE: 2001-06-26
; PRIOR APPLICATION NUMBER: 60/367,002
; PRIOR FILING DATE: 2002-03-22
; NUMBER OF SEQ ID NOS: 9
; SEQ ID NO 4
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-945-853-4

```

```

Query Match          100.0%; Score 104; DB 5; Length 17;
Best Local Similarity 100.0%; Pred. No. 2e-08;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 CPPSFYGRNCEHDVRKE 17
        |||||
Db      1 CPPSFYGRNCEHDVRKE 17

```



A service of the National Library of Medicine  
and the National Institutes of Health

www.pubmed.gov

My NCBI  
[Sign In] [Register]

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Book

Search  for

Limits

Preview/Index

History

Clipboard

Details

**Note:** Performing your original search, *keyhole limpet hemocyanin and th1*, in PubMed will retrieve 145 citations.

Display  Show  Sort by  Send to

All: 1

Review: 0



☐ 1: J Cancer Res Clin Oncol. 2001 Oct;127 Suppl 2:R20-6.



Links

### Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience.

**Musselli C, Livingston PO, Ragupathi G.**

Memorial Sloan Kettering Cancer Center, Department of Tumor Vaccinology, New York, NY 10021, USA.

Passively administered and actively induced antibodies have been associated with the eradication of circulating tumor cells and micrometastases in mice and humans. We have identified a series of cell surface carbohydrate and peptide antigens on melanomas, sarcomas, and cancer of the breast, prostate, ovary, and lung tissues. We found that breaking tolerance toward these tumor antigens was best achieved using vaccines containing antigens chemically conjugated to keyhole limpet hemocyanin (KLH) plus a potent immunological adjuvant (QS-21). To date, by using this approach to vaccination, antibodies have been induced in patients against glycolipid antigens GM2, GD2, GD3, FucosylGM1, Globo H, and Lewis Y, and glycoprotein (mucin) antigens Tn, sialyl Tn, TF, and MUC1. More recently, in a comparative study we investigated the T cell response induced by MUC1-KLH conjugates. Although a MUC1-specific T cell response was not consistently detected in any patient, the role of KLH in orienting the cytokine environment was crucial. We were able to confirm that KLH in these conjugate vaccines induces a Th1 T cell response as demonstrated by the high anti-KLH INF-gamma secretion and the IgG1 and IgG3 subclasses of this high titer IgG antibodies induced. Clinical trials using KLH conjugated glycolipid and glycoprotein vaccines, are currently ongoing. These range from phase I/II single antigens trials with glycosylated MUC1, polysialic acid, synthetic Fucosyl GM1 and GD2, to phase II trials with a polyvalent vaccine containing six or seven antigens. Randomized phase II trials with polyvalent vaccines are planned for initiation in 2001-2002 in patients with ovarian, breast, and prostate cancer.

### Related Links

A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancer. [Cancer Immunother. 2003]

Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines. [Vaccine. 2002]

Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. [Vaccine. 2000]

Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. [Cancer Immunol Immunother. 2005]

Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines. [Vaccine. 2002]

See all Related Articles...